These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36057749)

  • 1. Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.
    King RL; Hsi ED; Chan WC; Piris MA; Cook JR; Scott DW; Swerdlow SH
    Virchows Arch; 2023 Jan; 482(1):193-205. PubMed ID: 36057749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas.
    Behdad A; Bailey NG
    Surg Pathol Clin; 2016 Mar; 9(1):41-54. PubMed ID: 26940267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic and pathologic characterization of MYC-rearranged B-cell lymphomas in pediatric and young adult patients.
    Gagnon MF; Bruehl FK; Sill DR; Meyer RG; Greipp PT; Hoppman NL; Xu X; Baughn LB; Peterson JF; McPhail ED; Ketterling RP; King RL
    J Hematop; 2024 Jun; 17(2):51-61. PubMed ID: 38561469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.
    Hüttl KS; Staiger AM; Richter J; Ott MM; Kalmbach S; Klapper W; Biesdorf AS; Trümper L; Rosenwald A; Ziepert M; Horn H; Ott G
    Virchows Arch; 2021 Sep; 479(3):575-583. PubMed ID: 33655392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
    Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade B-cell lymphoma with concurrent MYC rearrangement and 11q aberrations: clinicopathologic, cytogenetic, and molecular characterization of 4 cases.
    Shestakova A; Shao L; Smith LB; Ryan R; Bedell V; Murata-Collins J; Zhang W; Perry AM; Song JY
    Hum Pathol; 2023 Jun; 136():34-43. PubMed ID: 36997031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements.
    Alsharif R; Dunleavy K
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):587-596. PubMed ID: 31229156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of 2016 WHO classification in the diagnosis of paediatric high-grade
    Zhang L; Brown LE; Bowen LM; McCarthy LC; Cooley LD; Repnikova E; Gener MA; Garola R; August KJ; Hays JA; Zwick DL; Li W
    J Clin Pathol; 2020 Sep; 73(9):563-570. PubMed ID: 31964683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.
    Thirunavukkarasu B; Bal A; Prakash G; Malhotra P; Singh H; Das A
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):49-55. PubMed ID: 34456240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive B-cell non-Hodgkin lymphomas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
    Rodriguez-Pinilla SM; Dojcinov S; Dotlic S; Gibson SE; Hartmann S; Klimkowska M; Sabattini E; Tousseyn TA; de Jong D; Hsi ED
    Virchows Arch; 2024 Jan; 484(1):15-29. PubMed ID: 37530792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.
    Baptista MJ; Tapia G; Muñoz-Marmol AM; Muncunill J; Garcia O; Montoto S; Gribben JG; Calaminici M; Martinez A; Veloza L; Martínez-Trillos A; Aldamiz T; Menarguez J; Terol MJ; Ferrandez A; Alcoceba M; Briones J; González-Barca E; Climent F; Muntañola A; Moraleda JM; Provencio M; Abrisqueta P; Abella E; Colomo L; García-Ballesteros C; Garcia-Caro M; Sancho JM; Ribera JM; Mate JL; Navarro JT
    Histopathology; 2022 Dec; 81(6):826-840. PubMed ID: 36109172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].
    Gerhard-Hartmann E; Rosenwald A
    Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.
    Alduaij W; Collinge B; Ben-Neriah S; Jiang A; Hilton LK; Boyle M; Meissner B; Chong L; Miyata-Takata T; Slack GW; Farinha P; Craig JW; Lytle A; Savage KJ; Villa D; Gerrie AS; Freeman CL; Gascoyne RD; Connors JM; Morin RD; Sehn LH; Mungall AJ; Steidl C; Scott DW
    Blood; 2023 May; 141(20):2493-2507. PubMed ID: 36302166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
    Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
    Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
    Gebauer N; Bernard V; Feller AC; Merz H
    Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
    Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational landscape of high-grade B-cell lymphoma with
    Künstner A; Witte HM; Riedl J; Bernard V; Stölting S; Merz H; Olschewski V; Peter W; Ketzer J; Busch Y; Trojok P; Bubnoff NV; Busch H; Feller AC; Gebauer N
    Haematologica; 2022 Aug; 107(8):1850-1863. PubMed ID: 34788985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.